---
authors:
- Zimmerman, Hannah
- Vogl, Allison
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/38648820/
file_path: 2024/04/considerations-for-implementing-cabotegravir-apretude-as-pre.md
issue: '4'
keywords:
- HIV Infections
- Pre-Exposure Prophylaxis
- Humans
- Pyridines
- Pyridones
- Diketopiperazines
- HIV Integrase Inhibitors
- Anti-HIV Agents
last_updated: '2025-07-30'
mesh_terms:
- Humans
- HIV Infections
- Pyridones
- Pre-Exposure Prophylaxis
- Pyridines
- HIV Integrase Inhibitors
- Anti-HIV Agents
- Diketopiperazines
original_format: PubMed
pages: '296'
patient_population: Adults
peer_reviewed: true
pmid: '38648820'
processed_date: '2025-07-30'
publication_date: '2024-04-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-10'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- editorial
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Considerations for Implementing Cabotegravir (Apretude) as PrEP for HIV Infection.
topics:
- Family Medicine
volume: '109'
publication_types: &id001
- Letter
- Comment
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '38648820'
  title: Considerations for Implementing Cabotegravir (Apretude) as PrEP for HIV Infection.
  authors:
  - last_name: Zimmerman
    fore_name: Hannah
    initials: H
    affiliation: Pittsburgh, Penn.
  - last_name: Vogl
    fore_name: Allison
    initials: A
    affiliation: McKeesport, Penn.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '109'
    issue: '4'
  publication_info:
    year: '2024'
    month: '04'
    full_date: '2024-04-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: HIV Infections
    major_topic: true
    qualifiers:
    - qualifier: prevention & control
      major_topic: false
  - descriptor: Pyridones
    major_topic: true
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Pre-Exposure Prophylaxis
    major_topic: false
    qualifiers:
    - qualifier: methods
      major_topic: false
  - descriptor: Pyridines
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: HIV Integrase Inhibitors
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
    - qualifier: administration & dosage
      major_topic: false
  - descriptor: Anti-HIV Agents
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Diketopiperazines
    major_topic: true
  publication_types: *id001
related_articles:
- pmid: '38648820'
  title: Considerations for Implementing Cabotegravir (Apretude) as PrEP for HIV Infection.
  authors:
  - name: Zimmerman H
    authtype: Author
    clusterid: ''
  - name: Vogl A
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2024 Apr
- pmid: '35171897'
  title: Cabotegravir (Apretude) for HIV-1 pre-exposure prophylaxis.
  authors: []
  source: Med Lett Drugs Ther
  pubdate: 2022 Feb 21
- pmid: '37192084'
  title: Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection.
  authors:
  - name: El-Haddad A
    authtype: Author
    clusterid: ''
  - name: Erlich D
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2023 May
- pmid: '35762372'
  title: 'Promises and challenges: cabotegravir for preexposure prophylaxis.'
  authors:
  - name: Spinelli MA
    authtype: Author
    clusterid: ''
  - name: Grinsztejn B
    authtype: Author
    clusterid: ''
  - name: Landovitz RJ
    authtype: Author
    clusterid: ''
  source: Curr Opin HIV AIDS
  pubdate: 2022 Jul 1
- pmid: '35157006'
  title: 'Long-Acting Cabotegravir for HIV Prevention: Issues of Access, Cost, and
    Equity.'
  authors:
  - name: Sharfstein JM
    authtype: Author
    clusterid: ''
  - name: Killelea A
    authtype: Author
    clusterid: ''
  - name: Dangerfield D
    authtype: Author
    clusterid: ''
  source: JAMA
  pubdate: 2022 Mar 8
---

# Considerations for Implementing Cabotegravir (Apretude) as PrEP for HIV Infection.

**Authors:** Zimmerman, Hannah, Vogl, Allison

**Published in:** American family physician | Vol. 109, No. 4 | 2024-04-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/38648820/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Humans, HIV Infections, Pyridones, Pre-Exposure Prophylaxis, Pyridines, HIV Integrase Inhibitors, Anti-HIV Agents, Diketopiperazines

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/38648820/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
